Yaz, Yasmin Blood-Clot Allegation Attorney: Resource4thePeople Encouraged by Continued Progress of Consolidated Federal Lawsuits
December 05, 2013 --
San Diego, CA (PRWEB) December 05, 2013
Resource4thePeople announced today its latest update for consumers who may be affected by allegations that that the popular contraceptives Yaz and Yasmin may cause life-threatening blood-clotting problems.
Among the latest developments is a decrease in the number of Yaz and Yasmin lawsuits* contained in a federal multi-district litigation in which cases from women across the country with similar allegations of blood-clotting problems have been consolidated.
Figures provided by the U.S. Judicial Panel on Multidistrict Litigation show that as of the end of the latest reporting period -- Nov. 18, 2013 -- there were 9,837 Yaz and Yasmin lawsuits remaining.** This is a decrease of 36 cases from the last reporting period in October.
"With the news that the manufacturers of these contraceptives is continuing to pay large amounts of money to settle these cases it is to be expected that there will be a decrease in the number of cases in the multidistrict litigation," said Resource4thePeople.
"While we encourage settlements that are favorable to the women involved in these life-threatening allegations we are also announcing that we will continue to offer free consultations to other women who have been affected but have not yet become part of the litigation."
The scope of the settlements of these lawsuits is reflected in the latest financial report*** from pharmaceutical giant Bayer, the manufacturer of Yaz and Yasmin contraceptives. It shows that the company has agreed to pay out nearly $1.6 billion so far to settle cases in the huge U.S. federal court multidistrict litigation.*
The progress of the settlements was recently reported to Judge David R. Herndon, in the U.S. District Court in the Southern District of Illinois, at a Nov. 14, 2013 status hearing at which attorneys for the plaintiffs and those representing the drugs' manufacturer, Bayer Pharmaceuticals briefed him on the progress of the litigation.
The judge told lawyers he would schedule another status conference for a further update, according to the court file.
"We encourage the resolution of cases and as this litigation progresses we will continue to offer experienced, aggressive representation on behalf of women who may have been affected by these allegations," said Resource4thePeople.
The figures about legal costs involving thousands of lawsuits alleging that the contraceptives have caused life-threatening blood-clotting problems were detailed in pharmaceutical giant Bayer's stockholder newsletter for the third quarter of 2013.
The massive payoffs were included in the Oct. 31, 2013 posting informing investors about the financial progress of the company, including an update of its legal costs.
"This is a huge amount of money and shows the extent of how significant the allegations about blood-clotting made by thousands of women are and how they are being compensated for a possibly fatal condition," said Resource4thePeople.
In the third quarter financial report Bayer reported the following details:
"As of October 18, 2013, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 7,660 claimants in the U.S. for a total amount of about US$1.575 billion. Bayer has only been settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case-specific analysis of medical records on a rolling basis. Such injuries are alleged by about 2,300 of the pending unsettled claimants. Bayer will continue to consider the option of settling such individual lawsuits in the U.S. on a case-by-case basis."
Bayer also has agreed to pay up to $24 million to settle other lawsuits in the multidistrict litigation involving allegations over gall bladder side effects, according to the court file in the litigation before Judge Herndon, according to the court file.
These settlements are a different component of this consolidated litigation in Illinois in which plaintiffs claimed that they suffered gall bladder injuries because they used Yaz and Yasmin as contraceptives.
Meanwhile, as a Sept. 15, 2013 article**** in the Chicago Tribune points out, federal officials are being asked to escalate warnings about possible blood-clotting problems associated with the contraceptives and at least one consumer non-profit organization has called for the products to be pulled from the marketplace.
The concerns raised by womens and consumer groups center focus on the same allegations made in the Yaz and Yasmin lawsuits --- that the use of these birth control pills may pose life-threatening side effects to the women who use them, said Resource4thePeople.
The Chicago Tribune article questioned the effectiveness and safety of Yaz and Yasmin contraceptives and cited increased concern about the products from womens groups:
Some women's health advocates want a stronger, black-box warning that is more likely to be noticed, the Tribune reported. The advocacy group Public Citizen, meanwhile, has placed drugs containing drospirenone including Yaz, Yasmin, Gianvi and Zarah on its do not use list because they can cause increased blood levels of potassium and (are) no more effective than other oral contraceptives in preventing pregnancy. On the Internet, people who call themselves Yaz survivors post accounts of their experiences."
In a related matter, the Canadian Broadcasting Company reported that physicians there are linking Yaz and Yasmin to 23 deaths. In a June 12, 2013 posting***** The CBC said that "According to documents obtained from Health Canada, doctors and pharmacists say Yaz and Yasmin are suspected in the deaths of the women, who mostly died suddenly from blood clots."
Health Canada is the Canadian equivalent to the FDA, which, on April 10, 2012, issued a Health Warning informing consumers and physicians about possible Yaz and Yasmin blood clotting side effects.******
*In re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation MDL No. 2100, U.S. District Court, Southern District of Illinois
Read the full story at http://www.prweb.com/releases/2013/12/prweb11386127.htm.